This study is available free. Just click on this link to download it. As a way of background, this is the second Phase 3 study for ISTURISA (osilodrostat). The first phase 3 study, LINC 3,
To launch the eighth season of the Pituitary World News podcast, we welcome to our microphones, Brandy. Brandy has quite a story to tell us about her battle with Cushing’s disease.
In the last podcast in the series on the drugs available to manage hypercortisolism, Dr. Blevins discusses mifepristone, trade name Korlym®.
This is the fourth podcast in a series of five on medications to treat Cushing’s disease. Today Dr. Blevins discusses Pasireotide, trade names Signifor and Signifor LAR.
Our third podcast in the series is on osilodrostat (trade name Isturisa®), a drug approved by the FDA in the US and the European Medicines Agency (EMA) to treat hypercortisolism in patients who are not candidates for surgery or those that surgery did not work. In this podcast, Dr. BLevins takes us inside his clinical practice to share his experiences with the drug.
The second podcast in our series on the medical management of hypercortisolism focuses on the drug metyrapone. Dr. Blevins discusses the drug uses, how it works, and its side effects.
Coming up next, a discussion on the drug Isturiza® (osilodrostat).
This is the first in our series of five podcasts on the medical management of Hypercortisolism due to Cushing’s disease. Today Dr. Blevins discusses the drug Ketoconazole. Tune in tomorrow to listen to the second podcast in the series on the use of Metyrapone, and on Monday, don’t miss the podcast on Isturisa® (osilodrostat).
Today we welcome three renowned experts in the development of drugs to treat hypercortisolism. Dr. Blevins and I discuss their research, clinical trials, challenges, and opportunities for these essential medications that could immensely affect patient well-being and quality of life. This discussion touches on the fascinating details of hypercortisolism and the developments now and in the future.
Dr. Lewis Blevins’ discussion on the postoperative evaluation and management of patients with hypercortisolism is technical and directed to physicians, but we encourage everyone to listen to it.
From the editor’s desk – For organizations in the pituitary space, we believe it is critically important to reach out to a broader audience to make the case that these conditions, although classified as rare,